Table 1.

Baseline characteristics of the study obese patients stratified by the presence of MS diagnosed according to the National Cholesterol Education Program-Adult Treatment Panel III criteria

TotalNon-MSMS
Male/female152/19133/59119/132
Age (years)52.1 ± 0.848.8 ± 1.553.2 ± 0.9a
BMI (kg/m2)31.2 ± 0.330.7 ± 0.731.4 ± 0.4
Waist circumference (cm)100 ± 0.897.6 ± 1.9101 ± 0.8a
Systolic blood pressure (mmHg)139 ± 0.9130 ± 1.5143 ± 1.1b
Diastolic blood pressure (mmHg)82.5 ± 0.777.6 ± 1.284.3 ± 0.8b
Fasting plasma glucose (mg/dl)132 ± 2.7108 ± 3.8140 ± 3.3b
HbA1c (%)6.72 ± 0.15.99 ± 0.16.98 ± 0.1b
IRI (μU/ml)21.0 ± 1.715.4 ± 1.923.0 ± 2.1a
Triglyceride (mg/dl)173 ± 7.1126 ± 5.6190 ± 9.2b
HDL-C (mg/dl)53.4 ± 0.758.6 ± 1.351.5 ± 0.8b
LDL-C (mg/dl)124 ± 1.7125 ± 2.9124 ± 2.1
Leptin (ng/ml)14.3 ± 0.713.4 ± 1.114.6 ± 0.8
Adiponectin (μg/ml)6.48 ± 0.26.64 ± 0.36.43 ± 0.2
CRP (μg/ml)1.41 ± 0.11.23 ± 0.11.47 ± 0.1
eGFR82.6 ± 1.485.4 ± 2.281.7 ± 1.7
S-CysC (mg/L)0.84 ± 0.020.78 ± 0.030.86 ± 0.02a
UACR (mg/g·Cr)99.2 ± 2337.5 ± 9.7122 ± 31a
UCCR0.77 ± 0.050.61 ± 0.020.82 ± 0.07a
U-B2MG (μg/L)186 ± 27117 ± 20212 ± 36a
U-NAG (U/L)4.17 ± 0.32.91 ± 0.34.63 ± 0.4a
CAVI7.85 ± 0.17.41 ± 0.28.02 ± 0.1b
Proportion of
    hypertension (%)77.046.793.2b
    diabetes (%)60.621.780.1b
    dyslipidemia (%)62.223.981.3b
    chronic kidney disease (%)15.75.419.5b
    taking calcium antagonist (%)25.410.932.7b
    taking ACE/ARB (%)31.213.140.2b
    taking antidiabetic medications (%)45.119.657.8b
    taking statins (%)25.06.534.3b
  • The data are expressed as the means ± SEM. ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker.

  • a P < 0.05 versus non-MS.

  • b P < 0.001 versus non-MS.